DiaSorin S.p.A. (DSRLF)
USD 109.01
(0.0%)
USD 109.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 333.39 Million EUR | -27.87% |
| 2022 | 536.79 Million USD | -10.55% |
| 2021 | 600.07 Million USD | 25.15% |
| 2020 | 479.49 Million USD | 53.05% |
| 2019 | 313.28 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 205.92 Million EUR | 18.34% |
| 2024 Q1 | 97.08 Million EUR | -22.68% |
| 2023 FY | - USD | -27.87% |
| 2023 Q2 | 212.91 Million USD | 227.06% |
| 2023 Q4 | 177.46 Million USD | 205.98% |
| 2023 Q1 | 65.1 Million EUR | -75.59% |
| 2023 Q3 | 58 Million EUR | -72.76% |
| 2022 Q2 | 270.6 Million USD | 83.35% |
| 2022 Q1 | 147.59 Million EUR | -49.79% |
| 2022 FY | - USD | -10.55% |
| 2022 Q4 | 266.66 Million USD | 196.29% |
| 2022 Q3 | 90 Million EUR | -66.74% |
| 2021 Q1 | 134.51 Million EUR | -42.12% |
| 2021 Q2 | 246.58 Million EUR | 83.32% |
| 2021 Q3 | 146.09 Million EUR | -40.75% |
| 2021 Q4 | 293.95 Million EUR | 101.21% |
| 2021 FY | - USD | 25.15% |
| 2020 Q2 | 159.5 Million EUR | 136.35% |
| 2020 Q4 | 232.38 Million EUR | 94.8% |
| 2020 Q3 | 119.29 Million EUR | -25.21% |
| 2020 FY | - USD | 53.05% |
| 2020 Q1 | 67.48 Million EUR | -52.45% |
| 2019 Q1 | 72.84 Million EUR | -6.41% |
| 2019 FY | - USD | 0.0% |
| 2019 Q4 | 141.91 Million EUR | 94.47% |
| 2019 Q3 | 72.97 Million EUR | -55.31% |
| 2019 Q2 | 163.28 Million EUR | 124.15% |
| 2018 Q2 | 74.41 Million EUR | -3.59% |
| 2018 Q1 | 77.18 Million EUR | -2.41% |
| 2018 Q4 | 77.83 Million EUR | 15.27% |
| 2018 Q3 | 67.52 Million EUR | -9.27% |
| 2017 Q3 | 64.12 Million EUR | -12.47% |
| 2017 Q1 | 64.17 Million EUR | 5.02% |
| 2017 Q4 | 79.09 Million EUR | 23.36% |
| 2017 Q2 | 73.25 Million EUR | 14.15% |
| 2016 Q4 | 61.1 Million EUR | 5.49% |
| 2016 Q2 | 60.01 Million EUR | 10.19% |
| 2016 Q1 | 54.46 Million EUR | 2.33% |
| 2016 Q3 | 57.93 Million EUR | -3.47% |
| 2015 Q2 | 54.79 Million EUR | 20.32% |
| 2015 Q3 | 52.97 Million EUR | -3.32% |
| 2015 Q4 | 53.22 Million EUR | 0.47% |
| 2015 Q1 | 45.53 Million EUR | -10.76% |
| 2014 Q2 | 53.92 Million EUR | 2.95% |
| 2014 Q3 | 48.74 Million EUR | -9.61% |
| 2014 Q4 | 51.02 Million EUR | 4.68% |
| 2014 Q1 | 52.38 Million EUR | -7.31% |
| 2013 Q2 | 58.01 Million EUR | 12.81% |
| 2013 Q4 | 56.51 Million EUR | 7.5% |
| 2013 Q1 | 51.42 Million EUR | 0.0% |
| 2013 Q3 | 52.56 Million EUR | -9.39% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | 28766.978% |
| Arrayit Corporation | -3.07 Million USD | 10933.387% |
| Atlantic International Corp. | -5.38 Million USD | 6285.977% |
| Biocept, Inc. | -30.24 Million USD | 1202.467% |
| Bioqual, Inc. | 3.03 Million USD | -10895.071% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | 44120.063% |
| DermTech, Inc. | -97.89 Million USD | 440.573% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 88.559% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 1747.018% |
| iMD Companies, Inc. | -154.65 Thousand USD | 215669.062% |
| IDenta Corp. | 71.58 Thousand USD | -465622.764% |
| Interpace Biosciences, Inc. | 3.83 Million USD | -8589.001% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | -861613.505% |
| InVitro International | 6680.00 USD | -4990872.38% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 6233.13% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | 2747726.133% |
| Medical Imaging Corp. | -896.74 Thousand USD | 37278.693% |
| NovelStem International Corp. | -3.78 Million USD | 8906.515% |
| Optigenex Inc. | -1.18 Million USD | 28193.892% |
| PharmChem, Inc. | 1.05 Million USD | -31537.293% |
| Proteome Sciences plc | -1.13 Million USD | 29422.511% |
| Response Genetics, Inc | -19.66 Million USD | 1795.296% |
| Rennova Health, Inc. | -234.81 Thousand USD | 142082.818% |
| RushNet, Inc. | -614.85 Thousand USD | 54323.936% |
| ScreenPro Security Inc. | -3.43 Million USD | 9806.193% |
| Stella Diagnostics Inc. | -5.7 Million USD | 5941.455% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 3346.275% |
| Todos Medical Ltd. | -9.39 Million USD | 3649.041% |